公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2011 | Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS) | Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG ; Mok T.S.K. | Journal of Clinical Oncology | 1256 | 1128 | |
2017 | Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC | Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG ; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. | Lung Cancer | 48 | 38 | |
2009 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG ; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. | New England Journal of Medicine | 7325 | 6479 | |
2010 | The prevalence and assessment of ErbB2-positive breast cancer in Asia: A literature survey | Tan Y.O; Han S; YEN-SHEN LU ; Yip C.-H; Sunpaweravong P; Jeong J; Caguioa P.B; Aggarwal S; Yeoh E.M; Moon H. | Cancer | 17 | 16 |